The Economic Burden of Atherosclerotic Cardiovascular Disease in Italy

被引:1
作者
Mennini, Francesco S. [1 ]
Scortichini, Matteo [1 ]
Colivicchi, Furio [2 ]
Maggioni, Aldo P. [3 ]
Sciattella, Paolo [1 ]
机构
[1] Univ Roma Tor Vergata, Fac Econ, Ctr Econ & Int Studies, Econ Evaluat & Hlth Technol Assessment, Via Columbia 2, I-00133 Rome, Italy
[2] San Filippo Neri Hosp, Div Cardiol, Rome, Italy
[3] ANMCO Res Ctr Heart Care Fdn, Florence, Italy
关键词
STATIN THERAPY; EZETIMIBE; RISK; ASSOCIATION; ADHERENCE; EFFICACY;
D O I
10.1007/s40261-024-01365-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundAtherosclerotic cardiovascular diseases remain the primary cause of mortality in Italy. Individuals with a history of acute coronary syndrome, peripheral arterial disease, and ischemic stroke/transient ischemic attack face an elevated risk of recurrent major adverse cardiovascular events, including mortality. The population aging, coupled with increasing risk factors such as diabetes mellitus and obesity, exacerbates the disease's economic impact.ObjectivesThis study aims to comprehensively assess the economic burden of atherosclerotic cardiovascular diseases in Italy, specifically focusing on direct healthcare costs.MethodsWe analyzed real-world data from administrative databases in the Marche region and Local Health Unit Umbria 2. The economic burden of patients discharged with acute coronary syndrome, peripheral arterial disease, and ischemic stroke/transient ischemic attack was evaluated, with a focus on direct costs associated with hospitalizations, drugs, and outpatient visits. Results were stratified by age, sex, comorbidities at baseline, and adherence to lipid-lowering therapy and antihypertensive agents.ResultsAnnually, nearly 350,000 patients were hospitalized for peripheral arterial disease, acute coronary syndrome, or ischemic stroke/transient ischemic attack. Direct health costs averaged <euro>7190 per patient over a 2-year follow-up, with hospitalizations accounting for nearly 70% of the total. Male patients incurred significantly higher costs (<euro>7467) than female patients (<euro>6625). Costs correlated positively with age and with the number of baseline comorbidities, with a range from <euro>5259 (0-1 comorbidities) to <euro>17,095 (4+ comorbidities). Costs were significantly lower in adherent subjects (<euro>6813) compared with non-adherent subjects (<euro>7757).ConclusionsThis study provides valuable insights into the economic implications of atherosclerotic cardiovascular diseases in Italy, emphasizing the necessity of a comprehensive approach to preventive measures, optimal medication adherence, and lifestyle modifications to mitigate its impact.
引用
收藏
页码:739 / 747
页数:9
相关论文
共 50 条
  • [21] Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease
    Cannon, Christopher P.
    Khan, Irfan
    Klimchak, Alexa C.
    Reynolds, Matthew R.
    Sanchez, Robert J.
    Sasiela, William J.
    JAMA CARDIOLOGY, 2017, 2 (09) : 959 - 966
  • [22] Primary and secondary prevention of atherosclerotic cardiovascular disease: A case-based approach
    Hariri, Essa H.
    Hammoud, Mazen M. Al
    Nissen, Steven E.
    Hammer, Donald F.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2022, 89 (09) : 513 - 522
  • [23] Lipid-lowering treatment among older patients with atherosclerotic cardiovascular disease
    Nanna, Michael G.
    Nelson, Adam J.
    Haynes, Kevin
    Shambhu, Sonali
    Eapen, Zubin
    Cziraky, Mark J.
    Calvert, Sara B.
    Pagidipati, Neha J.
    Granger, Christopher B.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2023, 71 (04) : 1243 - 1249
  • [24] Rationale, Criteria, and Impact of Identifying Extreme Risk in Patients with Atherosclerotic Cardiovascular Disease
    Zeng, Yuhong
    Zhao, Dong
    CARDIOLOGY DISCOVERY, 2022, 2 (02): : 114 - 123
  • [25] Inflammatory burden, lifestyle and atherosclerotic cardiovascular disease: insights from a population based cohort study
    Bay, Benjamin
    Blaum, Christopher
    Kellner, Caroline
    Kellen, Ramona Bei Der
    Ojeda, Francisco
    Waibel, Julia
    Arnold, Natalie
    Behrendt, Christian-A.
    Rimmele, David L.
    Thomalla, Goetz
    Twerenbold, Raphael
    Blankenberg, Stefan
    Zyriax, Birgit
    Brunner, Fabian J.
    Waldeyer, Christoph
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [26] Serum Paraoxonase-1 and Atherosclerotic Cardiovascular Disease
    Hidayet, Siho
    Askin, Lutfu
    COR ET VASA, 2024, 66 (06) : 608 - 614
  • [27] Multiomics tools for improved atherosclerotic cardiovascular disease management
    Sopic, Miron
    Vilne, Baiba
    Gerdts, Eva
    Trindade, Fabio
    Uchida, Shizuka
    Khatib, Soliman
    Wettinger, Stephanie Bezzina
    Devaux, Yvan
    Magni, Paolo
    TRENDS IN MOLECULAR MEDICINE, 2023, 29 (12) : 983 - 995
  • [28] Management of Hypercholesterolemia in Pregnant Women with Atherosclerotic Cardiovascular Disease
    Thobani, Aneesha
    Hassen, Lauren
    Mehta, Laxmi S.
    Agarwala, Anandita
    CURRENT ATHEROSCLEROSIS REPORTS, 2021, 23 (10)
  • [29] Usefulness of Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease
    Thobani, Aneesha
    Dhindsa, Devinder S.
    DeMoss, Benjamin D.
    Raad, Mohamad
    Sandesara, Pratik B.
    Sperling, Laurence S.
    Baer, Jefferson T.
    AMERICAN JOURNAL OF CARDIOLOGY, 2019, 124 (11) : 1785 - 1789
  • [30] Relationship between changes in coronary atherosclerotic plaque burden measured by intravascular ultrasound and cardiovascular disease outcomes: a systematic literature review
    Forbes, Carol
    Quek, Ruben G. W.
    Deshpande, Sohan
    Worthy, Gill
    Ross, Janine
    Kleijnen, Jos
    Gandra, Shravanthi R.
    Kassahun, Helina
    Wong, Nathan D.
    Nicholls, Stephen J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (06) : 1143 - 1150